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with a recent proposition that lipoprotein particles serve
as extracellular transporters of Wnts (Panakova et al.,
2005). Both in vivo and in vitro results indicate that un-
saturated fatty acylation results in displacement of pro-
teins, including Fyn and Gai, from membrane domains
within ordered lipid structures (Liang et al., 2001). Tak-
ing this into account, an alternative hypothesis is that
the unsaturated fatty acid acylation is generated by a
desaturase—modifying a saturated precursor that was
originally attached to the protein. Altering the properties
of the fatty acid chain could displace Wnt3a from the
membrane allowing it to be released from the cell or
inserted into lipoprotein particles.
The discovery by Takada et al. (2006) reported in this
issue ofDevelopmental Cell raises many intriguing ques-
tions. A key question is whether or not the S209 modifica-
tion is found in other Wnt proteins, also from other
species. The conservation of the serine and the sur-
rounding residues suggests that the answer will be yes.
Clarifying the role of Porcupine should be another prior-
ity. Does it play a role in both the acylation and secretion
of Wnts and are these two distinct steps? Can another
acyl-transferase partially substitute for Porcupine?
Which enzyme acylates the C77 residue? Is the failure
of the S209A mutant to be secreted because it is mis-
folded? What is the effect of mutating both the C77 and
the S209 to alanine? How should the discovery of a sec-
ond lipid modification affect the way we think of the inter-
action with recently described players in Wnt secretion:
Wls/Evi, the retromer complex, and lipoprotein parti-
cles? With respect to Wls, a recently described multi-
pass transmembrane protein dedicated to promoting the
Wnt secretion (Banziger et al., 2006; Bartscherer et al.,
2006), it will be important to determine what effect the
acylation at Ser209 has on its interaction with Wnts. Is
this required for the association with lipoprotein parti-
cles? The answers to these questions will provide insight
into the burgeoning field of exocytosis. The answers may
also provide us with the tools/targets that we can use to
control Wnt secretion thereby treating diseases where
aberrant secretion of Wnt proteins is implicated.
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Figure 1. A Schematic Overview of the Posi-
tion and Nature of the Posttranslational Mod-
ifications Found in Murine Wnt3a
The structures of the palmitate attached at
cysteine 77 (C77) and the newly identified pal-
mitoleic acid attached at serine 209 (S209)
are shown (not to scale). For the two possible
N-glycosylation sites at asparagines 87 and
298 (N87 and N298), the structure of the gly-
cosyl side chain is not known.
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752Oncogene Addiction:
Role of Signal Attenuation
Tumors can become dependent upon signaling by
oncogenes. In a recent issue of Cancer Cell, Sharma
et al. (2006b) reported that ‘‘oncogene addiction’’may be mediated by differential rates of signal attenu-
ation of proapoptotic and prosurvival pathways.
Human cancers often arise through a multistage pro-
cess involving gradual acquisition of numerous genetic
alterations, such as activating mutations of oncogenes
and inactivating mutations of tumor suppressor genes.
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753Interestingly and surprisingly, not all mutations are cre-
ated equal and some tumors are physiologically de-
pendent on (addicted to) the uninterrupted activity of a
single mutated oncogene for tumor maintenance. This
widespread and important phenomenon, termed ‘‘on-
cogene addiction’’ (Weinstein, 2002), has been well
documented in multiple mouse tumor models, cancer
cell lines, and human clinical trials involving specific
molecularly targeted inhibitors (Weinstein and Joe,
2006). Disruption of the respective oncogene conse-
quently leads to apoptosis, selective growth arrest,
and/or differentiation of the malignant cells. For treat-
ment purposes, these activated oncogenes and the cel-
lular pathways hijacked by them make attractive thera-
peutic targets. This is probably best illustrated by
chronic myeloid leukemia and the selective tyrosine ki-
nase inhibitor Gleevec that preferentially and dramati-
cally acts on tumor cells (addicted to the tyrosine kinase
BCR-ABL) and causes rapid cancer regression with only
limited side effects (Druker et al., 2001).
It has become commonplace to regard oncogene ad-
diction as a passive dependency of cancer cells on the
activity of the activated oncogene for sustained survival
and proliferation. Consequently, tumor cells, due to
their ‘‘bizarre circuitry’’ (Weinstein, 2000), irrevocably
default to an apoptotic outcome in response to onco-
gene inactivation, leading to complete tumor regres-
sion. However, mechanistic aspects of this phenome-
non remain unclear.
To examine a potential mechanism for oncogene ad-
diction, Sharma et al. (2006b) present initial experimen-
tal evidence that provides an interesting twist to the
oncogene addiction hypothesis, referring to their pro-
posed potential molecular mechanism as the ‘‘onco-
genic shock model.’’ In this scenario, the proapoptotic
outcome upon oncogene disruption results from coor-
dinated differences in the decay of proapoptotic (long-
lived) and prosurvival/proproliferation (short-lived)
signals. This mechanism requires that both kinds of sig-
nals emanate from the very same oncogenic source and
neutralize each other to maintain tumor cell proliferation
and survival. Moreover, the authors suggest that the
temporary signaling imbalance accompanying acute
oncogene inactivation provides a relatively narrow
window of reversibility during a critical transition period,
which is dependent on the occurrence of a counteract-
ing survival signal to protect the cell from an apoptotic
outcome (Sharma et al., 2006a).
The studies presented are primarily based on the
analysis of the time course of signaling mediated by a
limited subset of downstream prosurvival (Akt, ERK,
and STAT3/5) and proapoptotic (p38) effectors, as re-
flected by their phosphorylation status (Sharma et al.,
2006b). These investigators detect a common profile
of differential signal attenuation upon acute oncogene
inactivation in different cell culture models (Scr-, BCR-
ABL-, and EGFR-dependent cells) and also in a human
cancer cell line that harbors a mutated EGF receptor.
In each case, ‘‘oncogenic shock’’ is associated with
an immediate loss of prosurvival signaling that is suffi-
cient to shift the balance of life and death in favor of
cell death. As simultaneous treatment of an EGFR-
dependent cancer cell line with an EGFR-kinase inhibi-
tor (gefinitib) and a phosphatase inhibitor (okadaic acid)suppresses activation of both the EGFR and down-
stream kinases (Akt, ERK, and p38), it appears plausible
that both kinase and phosphatase activities are required
to maintain a delicate balance of the net phosphoryla-
tion status of downstream signaling mediators, which,
in turn, may dictate their steady-state kinetic properties.
The data presented by Sharma et al. (2006b) can be
interpreted in the context of the regulation of the time
course of MAPK signaling and its role in carcinogenesis.
Signal intensity and duration are modulated by a variety
of factors (cell-surface receptor density, expression
levels of scaffolding proteins, extracellular matrix, and
interplay of kinases and phosphatases). Differences in
amplitude and time course of signaling are a determin-
ing factor in biological specificity (Marshall, 1995).
Mechanisms that account for the effects of the time
course of signaling intensity may involve thresholds
for responses (Pouyssegur et al., 2002). One molecular
mechanism that illustrates how differences in MAPK ac-
tivation kinetics are sensed and interpreted by the cell
has been reported. Murphy et al. (2002) have estab-
lished that the immediate-early gene product c-Fos
functions as a molecular sensor for MAPK signal dura-
tion that can distinguish between transient and sus-
tained signaling. The time course of signal transduction
has also been implicated in the control of the JNK signal
transduction pathway. The use of chemical genetic
analysis to dissect signal transduction by the JNK path-
way has revealed that transient activation of JNK can
mediate survival responses while sustained activation
of JNK can cause cell death (Ventura et al., 2006).
The concept of oncogenic shock proposed by Sharma
et al. (2006a, 2006b) is an hypothesis. At present, the data
presented fall short of a direct test of this hypothesis. A
difference in time course of prosurvival and proapoptotic
signaling is observed, but a mechanistic test has not yet
been achieved. Nevertheless, this hypothesis is valuable
because it points toward possible underlying mecha-
nisms. Furthermore, like the oncogene addiction model,
the oncogenic shock model has clinical implications for
the use of cancer therapies that specifically target onco-
genic signal transduction pathways. The oncogenic
shock hypothesis suggests that drugs targeted toward
downstream signaling molecules may be utilized to shift
the balance toward proapoptotic outcomes. Moreover,
the repeated creation of such transient signaling imbal-
ances may be therapeutically beneficial.
One question that should be addressed in future stud-
ies is whether imbalances in signal transduction that
are proposed to cause oncogenic shock may also con-
tribute to other cellular processes in tumor cells in re-
sponse to oncogene deactivation, including senes-
cence and differentiation.
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A Wapl a Day
Keeps the Sisters Apart:
Wapl and Cohesin Dynamics
Sister chromatids are held together by the cohesin
complex from the time they are made until cell divi-
sion. In recent articles published in Cell and Current
Biology, the characterization of Wapl, a newly iden-
tified cohesin-interacting protein, suggests that a
dynamic interaction between the cohesin complex
and chromatin is important for normal regulation of
sister chromatid cohesion.
Prior to eukaryotic cell division, the genome is dupli-
cated, and the two copies of each chromosome are
held together until the cell splits in two. This phenome-
non, referred to as ‘‘sister chromatid cohesion,’’ ensures
that chromosome partitioning is accurate in both mei-
otic and mitotic cells and plays an important role in
DNA repair. In metazoans, the impact of sister chroma-
tid cohesion is most easily visualized during entry into
mitosis. As chromosomes begin to condense, sister
chromatids are so closely associated that they cannot
be distinguished. As prophase continues, chromo-
somes further condense, and the chromosome arms re-
solve into two discrete, parallel structures. Eventually
arm cohesion is dissolved and chromatids remain held
together only at the centromere region, resulting in the
formation of an X-shaped mitotic chromosome.
Cohesion is established during DNA replication and is
mediated by a large, multisubunit complex called cohe-
sin. The cohesin complex binds to the chromatin in telo-
phase and remains associated throughout S phase, G2,
and into mitosis. In vertebrates, the bulk of cohesin is
removed from the chromosomes in prophase following
mitotic phosphorylation. Centromeric cohesin is resis-
tant to this removal and is only removed by regulated
proteolysis of one of its subunits at the metaphase-
anaphase transition. At this time, all remaining cohesin is
removed, and sister chromatids move to opposite poles
of the dividing cell (reviewed in Uhlmann, 2003).
The exact nature of the cohesin-DNA interaction
remains poorly understood, though several lines of evi-
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with the DNA (Ivanov and Nasmyth, 2005). Just how
such an arrangement would allow for passage of the
replication fork is not clear. One model predicts that
the interaction of the cohesin complex with DNA must
be dynamic until after replication, when cohesion is es-
tablished. Gerlich et al. have recently demonstrated the
presence of two pools of chromatin-associated cohesin
in interphase cells: a ‘‘fast’’ pool that is found through-
out interphase, and a ‘‘slow’’ pool of cohesin found
only during G2. These data suggested that something
happens to ‘‘lock’’ a fraction of the chromatin-associ-
ated cohesin onto chromosomes during or after DNA
replication (Gerlich et al., 2006). This pool may represent
cohesin that has ‘‘established’’ cohesion. Studies in
yeast have shown that cohesin can be detected on re-
gions of the chromosome distinct from the sites where
it is loaded, suggesting that cohesin ‘‘sliding’’ may con-
tribute to cohesin dynamics (Lengronne et al., 2004).
How might cohesin dynamics be controlled? Two new
papers describing the function of a protein called Wapl
provide some intriguing insight into this problem (Kueng
et al., 2006; Gandhi et al., 2006). Kueng et al. identified
Wapl based on its physical interaction with the cohesin
complex. Genetic experiments in Drosophila had sug-
gested previously that this protein plays a role in chro-
mosome structure and segregation (Dobie et al., 2001;
Verni et al., 2000), and experiments in mice had sug-
gested that Wapl overexpression could promote tumor-
igenesis (Oikawa et al., 2004). Wapl may be related to
Rad61p of the yeast, a protein with roles in DNA repair,
cohesion and chromosome segregation. Until now the
molecular function of the Wapl family of proteins has
largely been unstudied.
Both groups show that depletion of the Wapl protein
prevents the normal prophase removal of cohesin from
chromosome arms. This results in unusual mitotic chro-
mosomes in which sister chromatids remain poorly re-
solved even in metaphase (Figure 1). This increase in
the levels of arm-associated cohesin is not dependent
upon the proteins that normally protect centromeric
cohesin, nor is it due to disrupted regulation of the pro-
phase pathway for removal of arm-associated cohesin.
Interestingly, in Wapl-depleted cells anaphase proceeds
in a relatively normal fashion, suggesting that the ana-
phase pathway is able to remove this excess mitotic co-
hesin appropriately. How might Wapl depletion result in
